Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database

eJHaem

article

Arleigh McCurdy¹  Martha Louzada²  Christopher P. Venner³  Alissa Visram¹  Esther Masih-Khan⁴  Moustafa Kardjadj⁵  Victor H. Jimenez-Zepeda⁶  Richard LeBlanc⁷  Michael Sebag⁸  Kevin Song⁹  Darrell White^1,10  Hira Mian^1,11  Julie Stakiw^1,12  Anthony Reiman^1,13  Muhammad Aslam^1,14  Rami Kotb^1,15  Engin Gul⁵  Donna Reece⁴ 

[1]The Ottawa Hospital

[2]London Regional Cancer Center

[3]Cross Cancer Institute, University of Alberta

[4]Princess Margaret Cancer Centre

[5]Canadian Myeloma Research Group

[6]Arnie Charbonneau Cancer Institute, University of Calgary

[7]Maisonneuve-Rosemont Hospital Research Centre, University of Montreal

[8]McGill University

[9]BC Cancer Agency, Vancouver General Hospital

[10]Queen Elizabeth II Health Sciences Centre, Dalhousie University

[11]Juravinski Cancer Center

[12]Saskatoon Cancer Centre, University of Saskatchewan

[13]Saint John Regional Hospital

[14]Allan Blair Cancer Centre

[15]Cancer Care Manitoba

关键词: carfilzomib;    multiple myeloma;    real-world data;   

DOI  :  10.1002/jha2.559

来源: Wiley

【 摘 要 】

Carfilzomib is an active and commonly used treatment in patients with multiple myeloma (MM). Using the Canadian Myeloma Research Group Database, we performed a retrospective observational study of patients treated with carfilzomib for relapse of MM in a real-world setting in Canada between years 2007 and 2020. A total of 445 patients were included in this study: the doublet (Kd/p, n  = 218) and triplets (KCd, n  = 88; KRd, n  = 99; KPd/p, n  = 40). One hundred and twenty-two (27%) received carfilzomib-based treatment in line 2, 133 (30%) in line 3, 90 (20%) in line 4, and 100 (23%) in line 5 or higher. Carfilzomib was dosed weekly in 40% of patients and twice weekly in 60%. The overall response rate of the entire cohort was 57.7%, with 33.6% of patients achieving very good partial response or better. Median progression-free survival for the overall cohort was 6.3 months with overall survival 19.7 months. This study provides a benchmark for carfilzomib-based regimens in the real world, demonstrating that these regimens are effective in treating patients with relapsed MM.

【 授权许可】

Unknown